Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials

Yasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Meta analysis of 5 colchicine RCTs (currently there are 29 RCTs) finding that treatment significantly reduced COVID-19 severity.
10 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, hospitalization Kow, and severity Yasmin.
Currently there are 54 colchicine for COVID-19 studies, showing 29% lower mortality [19‑39%], 29% lower ventilation [-15‑56%], 34% lower ICU admission [8‑52%], 19% lower hospitalization [11‑26%], and 9% more cases [-8‑29%].
Yasmin et al., 5 Apr 2022, peer-reviewed, 9 authors.
This PaperColchicineAll
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
Farah Yasmin, Hala Najeeb, Abdul Moeed, Wardah Hassan, Mahima Khatri, Muhammad Sohaib Asghar, Ahmed Kunwer Naveed, Waqas Ullah, Salim Surani
PLOS ONE, doi:10.1371/journal.pone.0266245
Background Colchicine has been used an effective anti-inflammatory drug to treat gout diseases. Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials. Methods Electronic databases (Pubmed, Google Scholar, and Cochrane) were systematically searched until June 2021 and RCTs were extracted. Outcomes of interest included allcause mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through the generic inverse variance formula while weighted mean differences were calculated using the Wan's method. P-values < 0.05 were considered statistically significant for all outcomes. Results A total population of 16,048 from five RCTs were included in the analysis. Of this, 7957 were randomized to colchicine, and 8091 received standard care, with an average age of 60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, 1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; I 2 = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = 0.84) among patients receiving colchicine or standard care.
References
Ali, Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19, Journal of Medical Virology, doi:10.1002/jmv.26097
Bikdeli, Madhavan, Jimenez, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol. Published, doi:10.1016/j.jacc.2020.04.031
Brunetti, Diawara, Tsai, Firestein, Nahass et al., Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19, Journal of clinical medicine, doi:10.3390/jcm9092961
Covid- ; Mehta, Mcauley, Brown, Sanchez, Tattersall et al., consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736%2820%2930628-0
Cronstein, Molad, Reibman, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils, J Clin Invest, doi:10.1172/JCI118147
Deftereos, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.13136
Della-Torre, Campochiaro, Cavalli, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218122
Della-Torre, Della-Torre, Kusanovic, Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol, doi:10.1016/j.clim.2020.108490
Fajgenbaum, June, Cytokine Storm, N. Engl. J. Med, doi:10.1056/NEJMra2026131
Ferro, Elefante, Baldini, COVID-19: the new challenge for rheumatologists, Clin Exp Rheumatol
Greber, Signalling in viral entry, Cell Mol. Life Sci, doi:10.1007/s00018-002-8453-3
Guan, Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Gupta, Zhao, Evans, The stimulation of thrombosis by hypoxia, Thromb Res, doi:10.1016/j.thromres.2019.07.013
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol, doi:10.1111/1440-1681.13488
Higgins, Thompson, Deeks, Altman, Measuring inconsistency in metaanalyses, British Medical Journal, doi:10.1136/bmj.327.7414.557
Landray, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, medRxiv, doi:10.1101/2021.05.18.21257267
Le, FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome, Oncologist, doi:10.1634/theoncologist.2018-0028
Leung, Hui, Kraus, Colchicine-Update on mechanisms of action and therapeutic uses, Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2015.06.013
Li, Liu, Mao, Predictive values of neutrophil to lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis, Crit Care, doi:10.1186/s13054-020-03374-8
Liberati, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, doi:10.1136/bmj.b2700
Lopes, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Mareev, Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiya, doi:10.18087/cardio.2021.2.n1560
Marnell, Mold, Clos, C-reactive protein: ligands, receptors, and role in inflammation, Clin Immunol, doi:10.1016/j.clim.2005.08.004
Martinon, Pe ´trilli, Mayor, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, doi:10.1038/nature04516
Miller, Becker, Grenfell, Metcalf, Disease and healthcare burden of COVID-19 in the United States, Nat. Med, doi:10.1038/s41591-020-0952-y
Notley, Tinlin, Sawyer, Begbie, Lillicrap, The factor VIII acute phase response requires the participation of NFκB and C/EBP, Thrombosis and Haemostasis
Parra-Medina, Sarmiento-Monroy, Rojas-Villarraga, Garavito, Montealegre-Gomez et al., Colchicine as a possible therapeutic option in COVID-19 infection, Clin. Rheumatol, doi:10.1007/s10067-020-05247-5
Qin, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin. Infect. Dis, doi:10.1093/cid/ciaa248
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Reyes, Hu, Teperman, Muskardin, Tardif et al., Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2020-219174
Scarsi, Piantoni, Colombo, Airo, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep, doi:10.1007/s40495-020-00225-6
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep, doi:10.1007/s40495-020-00225-6
Sproston, Ashworth, Role of C-reactive protein at sites of inflammation and infection, Frontiers in Immunology, doi:10.3389/fimmu.2018.00754
Sterne, RoB 2: A revised tool for assessing risk of bias in randomised trials, BMJ, doi:10.1136/bmj.l4898
Tardif, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir. Med, doi:10.1016/S2213-2600%2821%2900222-8
Tayer-Shifman, Ben-Chetrit, Familial Mediterranean fever and hypercoagulability, Mediterranean journal of hematology and infectious diseases, doi:10.4084/MJHID.2011.017
Turk, Turk, Malkan, Haznedaroglu, Three critical clinicobiological phases of the human SARS-associated coronavirus infections, Eur. Rev. Med. Pharmacol. Sci, doi:10.26355/eurrev%5F202008%5F22660
Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med. Res. Methodol, doi:10.1186/1471-2288-14-135
Wang, Wu, Zhang, C-reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infect Dis, doi:10.1093/ofid/ofaa153
Yao, D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study, J. Intensive Care, doi:10.1186/s40560-020-00466-z
Zhang, Li, Shen, Chen, Qi, Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin Drug Investig, doi:10.1007/s40261-020-00917-3
Zhang, Wu, Li, Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105954
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736%2820%2930566-3
{ 'DOI': '10.1371/journal.pone.0266245', 'ISSN': ['1932-6203'], 'URL': 'http://dx.doi.org/10.1371/journal.pone.0266245', 'abstract': '<jats:sec id="sec001">\n' '<jats:title>Background</jats:title>\n' '<jats:p>Colchicine has been used an effective anti-inflammatory drug to treat gout diseases. ' 'Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the ' 'cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the ' 'safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control ' 'trials.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec002">\n' '<jats:title>Methods</jats:title>\n' '<jats:p>Electronic databases (Pubmed, Google Scholar, and Cochrane) were systematically ' 'searched until June 2021 and RCTs were extracted. Outcomes of interest included all-cause ' 'mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. ' 'Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through ' 'the generic inverse variance formula while weighted mean differences were calculated using ' 'the Wan’s method. P-values &lt; 0.05 were considered statistically significant for all ' 'outcomes.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec003">\n' '<jats:title>Results</jats:title>\n' '<jats:p>A total population of 16,048 from five RCTs were included in the analysis. Of this, ' '7957 were randomized to colchicine, and 8091 received standard care, with an average age of ' '60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% ' 'CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). ' 'However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, ' '1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; ' 'I<jats:sup>2</jats:sup> = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = ' '0.84) among patients receiving colchicine or standard care.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec004">\n' '<jats:title>Conclusion</jats:title>\n' '<jats:p>Colchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, ' 'all-cause mortality and mechanical ventilation remaining seemingly unaffected. Thus, clinical ' 'trials need to be carried out that allow effective evaluation of colchicine in COVID-19 ' 'patients.</jats:p>\n' '</jats:sec>', 'author': [ {'affiliation': [], 'family': 'Yasmin', 'given': 'Farah', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0001-7075-4674', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Najeeb', 'given': 'Hala', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-4429-1391', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Moeed', 'given': 'Abdul', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hassan', 'given': 'Wardah', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Khatri', 'given': 'Mahima', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Asghar', 'given': 'Muhammad Sohaib', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4215-0600', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Naveed', 'given': 'Ahmed Kunwer', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ullah', 'given': 'Waqas', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7105-4266', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Surani', 'given': 'Salim', 'sequence': 'additional'}], 'container-title': ['PLOS ONE'], 'content-domain': {'crossmark-restriction': False, 'domain': ['www.plosone.org']}, 'created': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T17:52:03Z', 'timestamp': 1649181123000}, 'deposited': { 'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T17:53:09Z', 'timestamp': 1649181189000}, 'editor': [{'affiliation': [], 'family': 'Siddiqi', 'given': 'Tariq Jamal', 'sequence': 'first'}], 'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T18:13:08Z', 'timestamp': 1649182388822}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'electronic', 'value': '1932-6203'}], 'issue': '4', 'issued': {'date-parts': [[2022, 4, 5]]}, 'journal-issue': {'issue': '4', 'published-online': {'date-parts': [[2022, 4, 5]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T00:00:00Z', 'timestamp': 1649116800000}}], 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0266245', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '340', 'original-title': [], 'page': 'e0266245', 'prefix': '10.1371', 'published': {'date-parts': [[2022, 4, 5]]}, 'published-online': {'date-parts': [[2022, 4, 5]]}, 'publisher': 'Public Library of Science (PLoS)', 'reference': [ {'key': 'pone.0266245.ref001', 'unstructured': '“Timeline of WHO’s response to COVID-19”.'}, { 'key': 'pone.0266245.ref002', 'unstructured': '“WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) ' 'Dashboard With Vaccination Data.” https://covid19.who.int/ (accessed ' 'Jun. 08, 2021).'}, { 'key': 'pone.0266245.ref003', 'unstructured': '“Novel 2019 coronavirus genome—SARS-CoV-2 coronavirus—Virological”.'}, { 'DOI': '10.1038/s41591-020-0952-y', 'article-title': 'Disease and healthcare burden of COVID-19 in the United States', 'author': 'I. F. Miller', 'doi-asserted-by': 'crossref', 'first-page': '1212', 'issue': '8', 'journal-title': 'Nat. Med.', 'key': 'pone.0266245.ref004', 'volume': '26', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical Characteristics of Coronavirus Disease 2019 in China', 'author': 'W. Guan', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'issue': '18', 'journal-title': 'N. Engl. J. Med.', 'key': 'pone.0266245.ref005', 'volume': '382', 'year': '2020'}, { 'article-title': 'Three critical clinicobiological phases of the human SARS-associated ' 'coronavirus infections', 'author': 'C. Turk', 'first-page': '8606', 'issue': '16', 'journal-title': 'Eur. Rev. Med. Pharmacol. Sci.', 'key': 'pone.0266245.ref006', 'volume': '24', 'year': '2020'}, { 'DOI': '10.1093/cid/ciaa248', 'article-title': 'Dysregulation of immune response in patients with coronavirus 2019 ' '(COVID-19) in Wuhan, China', 'author': 'C. Qin', 'doi-asserted-by': 'crossref', 'first-page': '762', 'issue': '15', 'journal-title': 'Clin. Infect. Dis.', 'key': 'pone.0266245.ref007', 'volume': '71', 'year': '2020'}, { 'DOI': '10.1016/j.semarthrit.2015.06.013', 'article-title': 'Colchicine-Update on mechanisms of action and therapeutic uses', 'author': 'Y. Y. Leung', 'doi-asserted-by': 'crossref', 'first-page': '341', 'issue': '3', 'journal-title': 'Seminars in Arthritis and Rheumatism', 'key': 'pone.0266245.ref008', 'volume': '45', 'year': '2015'}, { 'DOI': '10.1056/NEJMra2026131', 'article-title': 'Cytokine Storm', 'author': 'D. C. Fajgenbaum', 'doi-asserted-by': 'crossref', 'first-page': '2255', 'issue': '23', 'journal-title': 'N. Engl. J. Med.', 'key': 'pone.0266245.ref009', 'volume': '383', 'year': '2020'}, { 'DOI': '10.1634/theoncologist.2018-0028', 'article-title': 'FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen ' 'Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release ' 'Syndrome', 'author': 'R. Q. Le', 'doi-asserted-by': 'crossref', 'first-page': '943', 'issue': '8', 'journal-title': 'Oncologist', 'key': 'pone.0266245.ref010', 'volume': '23', 'year': '2018'}, { 'article-title': 'D-dimer as a biomarker for disease severity and mortality in COVID-19 ' 'patients: A case control study', 'author': 'Y. Yao', 'first-page': '1', 'issue': '1', 'journal-title': 'J. Intensive Care', 'key': 'pone.0266245.ref011', 'volume': '8', 'year': '2020'}, { 'DOI': '10.1002/jmv.26097', 'article-title': 'Elevated level of C-reactive protein may be an early marker to predict ' 'risk for severity of COVID-19', 'author': 'N. Ali', 'doi-asserted-by': 'crossref', 'first-page': '2409', 'issue': '11', 'journal-title': 'Journal of Medical Virology', 'key': 'pone.0266245.ref012', 'volume': '92', 'year': '2020'}, { 'DOI': '10.3389/fimmu.2018.00754', 'article-title': 'Role of C-reactive protein at sites of inflammation and infection', 'author': 'N. R. Sproston', 'doi-asserted-by': 'crossref', 'first-page': '754', 'journal-title': 'Frontiers in Immunology', 'key': 'pone.0266245.ref013', 'volume': '9', 'year': '2018'}, { 'DOI': '10.1136/bmj.b2700', 'article-title': 'The PRISMA statement for reporting systematic reviews and meta-analyses ' 'of studies that evaluate healthcare interventions: explanation and ' 'elaboration.', 'author': 'A. Liberati', 'doi-asserted-by': 'crossref', 'journal-title': 'BMJ', 'key': 'pone.0266245.ref014', 'volume': '339', 'year': '2009'}, { 'key': 'pone.0266245.ref015', 'unstructured': '“Clinical Spectrum | COVID-19 Treatment Guidelines.” ' 'https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ ' '(accessed Jun. 18, 2021).'}, { 'article-title': 'RoB 2: A revised tool for assessing risk of bias in randomised trials', 'author': 'J. A. C. Sterne', 'journal-title': 'BMJ', 'key': 'pone.0266245.ref016', 'volume': '366', 'year': '2019'}, { 'DOI': '10.1186/1471-2288-14-135', 'article-title': 'Estimating the sample mean and standard deviation from the sample size, ' 'median, range and/or interquartile range', 'author': 'X. Wan', 'doi-asserted-by': 'crossref', 'first-page': '135', 'issue': '1', 'journal-title': 'BMC Med. Res. Methodol.', 'key': 'pone.0266245.ref017', 'volume': '14', 'year': '2014'}, { 'DOI': '10.1136/bmj.327.7414.557', 'article-title': 'Measuring inconsistency in meta-analyses', 'author': 'J. P. T. Higgins', 'doi-asserted-by': 'crossref', 'first-page': '557', 'issue': '7414', 'journal-title': 'British Medical Journal', 'key': 'pone.0266245.ref018', 'volume': '327', 'year': '2003'}, { 'DOI': '10.1136/rmdopen-2020-001455', 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: A ' 'randomised, double-blinded, placebo-controlled clinical trial', 'author': 'M. I. Lopes', 'doi-asserted-by': 'crossref', 'issue': '1', 'journal-title': 'RMD Open', 'key': 'pone.0266245.ref019', 'volume': '7', 'year': '2021'}, { 'article-title': 'Colchicine for community-treated patients with COVID-19 (COLCORONA): a ' 'phase 3, randomised, double-blinded, adaptive, placebo-controlled, ' 'multicentre trial', 'author': 'J.-C. Tardif', 'journal-title': 'Lancet Respir. Med.', 'key': 'pone.0266245.ref020', 'year': '2021'}, { 'DOI': '10.1001/jamanetworkopen.2020.13136', 'article-title': 'Effect of Colchicine vs Standard Care on Cardiac and Inflammatory ' 'Biomarkers and Clinical Outcomes in Patients Hospitalized with ' 'Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial', 'author': 'S. G. Deftereos', 'doi-asserted-by': 'crossref', 'issue': '6', 'journal-title': 'JAMA Netw. Open', 'key': 'pone.0266245.ref021', 'volume': '3'}, { 'article-title': 'Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'author': 'M. Landray', 'journal-title': 'medRxiv', 'key': 'pone.0266245.ref022', 'year': '2021'}, { 'DOI': '10.18087/cardio.2021.2.n1560', 'article-title': 'Proactive anti-inflammatory therapy with colchicine in the treatment of ' 'advanced stages of new coronavirus infection. The first results of the ' 'COLORIT study', 'author': 'V. Y. Mareev', 'doi-asserted-by': 'crossref', 'first-page': '15', 'issue': '2', 'journal-title': 'Kardiologiya', 'key': 'pone.0266245.ref023', 'volume': '61', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(20)30628-0', 'article-title': 'COVID- 19: consider cytokine storm syndromes and immunosuppression', 'author': 'HLH Across Speciality Collaboration UK', 'doi-asserted-by': 'crossref', 'first-page': '1033', 'journal-title': 'Lancet', 'key': 'pone.0266245.ref024', 'volume': '395', 'year': '2020'}, { 'article-title': 'IL-6 Inhibitors in the treatment of serious COVID- 19: a promising ' 'therapy?', 'author': 'S Atal', 'first-page': '223', 'journal-title': 'Pharmaceut Med', 'key': 'pone.0266245.ref025', 'volume': '34', 'year': '2020'}, { 'DOI': '10.1007/s40261-020-00917-3', 'article-title': 'Rational use of tocilizumab in the treatment of novel coronavirus ' 'pneumonia.', 'author': 'S Zhang', 'doi-asserted-by': 'crossref', 'first-page': '511', 'journal-title': 'Clin Drug Investig', 'key': 'pone.0266245.ref026', 'volume': '40', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.105954', 'article-title': 'Cytokine release syndrome in severe COVID-19: interleukin-6 receptor ' 'antagonist tocilizumab may be the key to reduce mortality', 'author': 'C Zhang', 'doi-asserted-by': 'crossref', 'first-page': '105954', 'journal-title': 'Int J Antimicrob Agents', 'key': 'pone.0266245.ref027', 'volume': '55', 'year': '2020'}, { 'article-title': 'COVID-19: the new challenge for rheumatologists', 'author': 'F Ferro', 'first-page': '175', 'journal-title': 'Clin Exp Rheumatol', 'key': 'pone.0266245.ref028', 'volume': '38', 'year': '2020'}, { 'DOI': '10.1016/j.clim.2020.108490', 'article-title': 'Treating COVID-19 with colchicine in community healthcare setting', 'author': 'E Della-Torre', 'doi-asserted-by': 'crossref', 'first-page': '108490', 'journal-title': 'Clin Immunol', 'key': 'pone.0266245.ref029', 'volume': '217', 'year': '2020'}, { 'DOI': '10.1007/s40495-020-00225-6', 'article-title': 'Colchicine in COVID-19: an old drug, new use', 'author': 'N Schlesinger', 'doi-asserted-by': 'crossref', 'first-page': '137', 'journal-title': 'Curr Pharmacol Rep', 'key': 'pone.0266245.ref030', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1007/s40495-020-00225-6', 'article-title': 'Colchicine in COVID-19: an old drug, new use', 'author': 'N Schlesinger', 'doi-asserted-by': 'crossref', 'first-page': '137', 'journal-title': 'Curr Pharmacol Rep.', 'key': 'pone.0266245.ref031', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1186/s13054-020-03374-8', 'article-title': 'Predictive values of neutrophil to lymphocyte ratio on disease severity ' 'and mortality in COVID-19 patients: a systematic review and ' 'meta-analysis', 'author': 'X Li', 'doi-asserted-by': 'crossref', 'first-page': '647', 'issue': '1', 'journal-title': 'Crit Care', 'key': 'pone.0266245.ref032', 'volume': '24', 'year': '2020'}, { 'article-title': 'Anti-inflammatory therapy for COVID-19 infection: the case for ' 'colchicine', 'author': 'AZ Reyes', 'journal-title': 'Ann Rheum Dis', 'key': 'pone.0266245.ref033', 'year': '2020'}, { 'DOI': '10.1111/1440-1681.13488', 'article-title': 'Colchicine treatment can improve outcomes of coronavirus disease 2019 ' '(COVID-19): A systematic review and meta-analysis', 'author': 'TI Hariyanto', 'doi-asserted-by': 'crossref', 'first-page': '823', 'journal-title': 'Clin Exp Pharmacol Physiol', 'key': 'pone.0266245.ref034', 'volume': '48', 'year': '2021'}, { 'DOI': '10.1136/annrheumdis-2020-218122', 'article-title': 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with ' 'systemic hyperinflammation: an open-label cohort study', 'author': 'E Della-Torre', 'doi-asserted-by': 'crossref', 'first-page': '1277', 'issue': '10', 'journal-title': 'Ann Rheum Dis', 'key': 'pone.0266245.ref035', 'volume': '79', 'year': '2020'}, { 'article-title': 'Association between treatment with colchicine and improved survival in ' 'a single-centre cohort of adult hospitalised patients with COVID-19 ' 'pneumonia and acute respiratory distress syndrome', 'author': 'M. Scarsi', 'journal-title': 'Annals of the Rheumatic Diseases, annrheumdis–2020–217712', 'key': 'pone.0266245.ref036', 'year': '2020'}, { 'article-title': 'Familial Mediterranean fever and hypercoagulability', 'author': 'OE Tayer-Shifman', 'issue': '1', 'journal-title': 'Mediterranean journal of hematology and infectious diseases', 'key': 'pone.0266245.ref037', 'volume': '3', 'year': '2011'}, { 'key': 'pone.0266245.ref038', 'unstructured': 'D-dimer: establishing a laboratory assay for ruling out venous ' 'thrombosis.'}, { 'DOI': '10.1055/s-0037-1613999', 'article-title': 'The factor VIII acute phase response requires the participation of NFκB ' 'and C/EBP', 'author': 'C. Notley', 'doi-asserted-by': 'crossref', 'first-page': '216', 'issue': '8', 'journal-title': 'Thrombosis and Haemostasis', 'key': 'pone.0266245.ref039', 'volume': '84', 'year': '2000'}, { 'DOI': '10.1172/JCI118147', 'article-title': 'Colchicine alters the quantitative and qualitative display of selectins ' 'on endothelial cells and neutrophils', 'author': 'BN Cronstein', 'doi-asserted-by': 'crossref', 'first-page': '994', 'journal-title': 'J Clin Invest', 'key': 'pone.0266245.ref040', 'volume': '96', 'year': '1995'}, { 'DOI': '10.1038/nature04516', 'article-title': 'Gout-associated uric acid crystals activate the NALP3 inflammasome', 'author': 'F Martinon', 'doi-asserted-by': 'crossref', 'first-page': '237', 'journal-title': 'Nature', 'key': 'pone.0266245.ref041', 'volume': '440', 'year': '2006'}, { 'DOI': '10.1016/j.thromres.2019.07.013', 'article-title': 'The stimulation of thrombosis by hypoxia', 'author': 'N Gupta', 'doi-asserted-by': 'crossref', 'first-page': '77', 'journal-title': 'Thromb Res', 'key': 'pone.0266245.ref042', 'volume': '181', 'year': '2019'}, { 'article-title': 'COVID-19 and thrombotic or thromboembolic disease: implications for ' 'prevention, antithrombotic therapy, and follow-up', 'author': 'B Bikdeli', 'journal-title': 'J Am Coll Cardiol', 'key': 'pone.0266245.ref043'}, { 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'author': 'F Zhou', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'issue': '10229', 'journal-title': 'Lancet', 'key': 'pone.0266245.ref044', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1016/j.clim.2005.08.004', 'article-title': 'C‐reactive protein: ligands, receptors, and role in inflammation', 'author': 'L Marnell', 'doi-asserted-by': 'crossref', 'first-page': '104', 'issue': '2', 'journal-title': 'Clin Immunol', 'key': 'pone.0266245.ref045', 'volume': '117', 'year': '2005'}, { 'DOI': '10.1093/ofid/ofaa153', 'article-title': 'C‐reactive protein level may predict the risk of COVID‐19 aggravation', 'author': 'G Wang', 'doi-asserted-by': 'crossref', 'issue': '5', 'journal-title': 'Open Forum Infect Dis', 'key': 'pone.0266245.ref046', 'volume': '7', 'year': '2020'}, { 'DOI': '10.3390/jcm9092961', 'article-title': 'Colchicine to Weather the Cytokine Storm in Hospitalized Patients with ' 'COVID-19', 'author': 'L Brunetti', 'doi-asserted-by': 'crossref', 'first-page': '2961', 'issue': '9', 'journal-title': 'Journal of clinical medicine', 'key': 'pone.0266245.ref047', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1007/s00018-002-8453-3', 'article-title': 'Signalling in viral entry', 'author': 'U.F. Greber', 'doi-asserted-by': 'crossref', 'first-page': '608', 'journal-title': 'Cell Mol. Life Sci', 'key': 'pone.0266245.ref048', 'volume': '59', 'year': '2002'}, { 'DOI': '10.1007/s10067-020-05247-5', 'article-title': 'Colchicine as a possible therapeutic option in COVID-19 infection', 'author': 'R. Parra-Medina', 'doi-asserted-by': 'crossref', 'first-page': '2485', 'journal-title': 'Clin. Rheumatol', 'key': 'pone.0266245.ref049', 'volume': '39', 'year': '2020'}, { 'DOI': '10.1136/annrheumdis-2020-219174', 'article-title': 'Anti-inflammatory therapy for COVID-19 infection: the case for ' 'colchicine', 'author': 'AZ Reyes', 'doi-asserted-by': 'crossref', 'first-page': '550', 'issue': '5', 'journal-title': 'Annals of the rheumatic diseases', 'key': 'pone.0266245.ref050', 'volume': '80', 'year': '2021'}], 'reference-count': 50, 'references-count': 50, 'relation': {}, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0266245'}}, 'score': 1, 'short-container-title': ['PLoS ONE'], 'short-title': [], 'source': 'Crossref', 'subject': ['Multidisciplinary'], 'subtitle': [], 'title': [ 'Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis ' 'of randomized control trials'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'volume': '17'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit